It is thought that efforts to treat RAS-driven cancers with MEK inhibitors have failed in part as inhibition of MEK reduces the activity of ERK1/2, resulting in the release of a negative feedback loop, thus increasing the activity of SOS1-dependent formation of GTP-bound RAS. This evidence concerns the gene SOS1 and cancer.